Clinically relevant anticancer polymer paclitaxel therapeutics

Cancers

Volumn 3, Issue 1, 2011, Pages 17-42

  Yang, Danbo ^a   Yu, Lei ^a,b   Van, Sang ^b  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b Biomedical Group   (United States)

Author keywords

Polymer paclitaxel conjugates; Polymer paclitaxel therapeutics; Polymeric micelles

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ESTRADIOL; ESTRAMUSTINE; GEMCITABINE; GENEXOL PM; MACROGOL; NANOPARTICLE; NAVELBINE; NK 105; PACLITAXEL; PACLITAXEL DERIVATIVE; PACLITAXEL GAMMA GLUTAMYLGLUTAMINE COPOLYMER; PACLITAXEL GLUTAMIC ACID COPOLYMER; PACLITAXEL HYDROXYPROPYLMETHACRYLAMIDE COPOLYMER; PACLITAXEL POLIGLUMEX; PNU 166945; POLYASPARTIC ACID; POLYLACTIDE; PREDNISONE; UNCLASSIFIED DRUG;

ANEMIA; BLOOD TOXICITY; BREAST ADENOCARCINOMA; BREAST CANCER; BREAST TUMOR; CANCER SURVIVAL; COLON CANCER; DIARRHEA; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG RELEASE; DRUG STRUCTURE; DRUG WITHDRAWAL; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; MOTOR NEUROPATHY; MYALGIA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; PERITONEUM CANCER; PROSTATE CANCER; REVIEW; SENSORY NEUROPATHY; SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; UTERINE TUBE CARCINOMA;

EID: 79953716272     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3010017     Document Type: Review

References (54)

1. Wani, M.C.; Taylor, H.L.; Wall, M.E. Coggon, P.; McPhail, A.T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 1971, 93, 2325-2327.
2. Park, S.R.; Oh, D.Y.; Kim, D.W.; Kim, T.Y.; Heo, D.S.; Bang, Y.J.; Kim, N.K.; Kang, W.K.; Kim, H.T.; Im, S.A.; Suh, J.H.; Kim, H.K.; Kim, H.K. A multi-center, late phase II clinical trial of Genexol® (paclitaxel) and cisplatin for patients with advanced gastric cancer. Oncol. Rep. 2004, 12, 1059-1064.
3. Sparreboom, A.; van Zuylen, L.; Brouwer, E.; Loos, W.J.; de Bruijn, P.; Gelderblom, H.; Pillay, M.; Nooter, K.; Stoter, G.; Verweij, J. Cremophor EL-mediated Alteration of Paclitaxel Distribution in Human Blood: Clinical Pharmacokinetic Implications. Cancer Res. 1999, 59, 1454-1457.
4. Lockich, J.; Anderson, J. Paclitaxel hypersensitivity reactions: A role for docetaxel substitution. Ann. Oncol. 1998, 9, 573-574.
5. Deutsch, H.M.; Glinski, J.A.; Hernandez, M.; Haugwitz, R.D.; Narayanan, V.L.; Suffness, M.; Zalkow, L.H. Synthesis of Congeners and Prodrugs. 3. Water-soluble Prodrugs of Taxol with Potent Antitumor Activity. J. Med. Chem. 1989, 32, 788-792.
6. Mathew, A.E.; Mejillano, M.R.; Nath, J.P.; Himes, R.H.; Stella, V.J. Synthesis and Evaluation of Some Water-Soluble Prodrugs and Derivatives of Taxol with Antitumor Activity. J. Med. Chem. 1992, 35, 145-151.
7. Nicolaou, K.C.; Dai, W.M.; Guy, R.K. Chemistry and Biology of Taxol. Angew. Chem. Int. Ed. Engl. 1994, 33, 15-44.
8. Duncan, R. The Dawning era of polymer therapeutics. Nat. Rev. Drug. Discov. 2003, 2, 347-360.
9. Haag, R.; Kratz, F. Polymer Therapeutics: Concepts and Applications. Angew. Chem. Int. Ed. Engl. 2006, 45, 1198-1215.
10. David, M.E.; Chen, Z.; Shin, D.M. Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat. Rev. Drug Discov. 2008, 7, 771-782.
11. Gros, L.; Ringsdorf, H.; Schupp, H. Polymeric antitumour agents on a molecular and on a cellular level? Angew. Chem. Int. Ed. Engl. 1981, 20, 305-325.
12. Meerum Terwogt, J.M.; ten Bokkel Huinink, W.W. Schellens, J.H.; Schot, M.; Mandjes, I.A.; Zurlo, M.G.; Rocchetti, M.; Rosing, H.; Koopman, F.J.; Beijnen, J.H. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs 2001, 12, 315-323.
13. Matsumura, Y.; Maeda, H. A New Concept for Macromolecular Therapeutics in Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins and the Anticancer Agent SMANCS. Cancer Res. 1986, 46, 6387-6392.
14. Boddy, A.V.; Plummer, E.R.; Todd, R.; Sludden, J.; Griffin, M.; Robson, L.; Cassidy, J.; Bissett, D.; Bernareggi, A.; Verrill, M.W.; Calvert, A.H. A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (Xyotax), Investigating Both 3-weekly and 2-Weekly Schedules. Clin. Cancer Res. 2005, 11, 7834-7840.
15. Li, C.; Yu, D.F.; Newman, R.A.; Cabral, F.; Stephens, L.C.; Hunter, N.; Milas, L.; Wallace, S. Complete Regression of Well-established Tumors Using a Novel Water-soluble Poly(L-Glutamic Acid)-Paclitaxel Conjugate. Cancer Res. 1998, 58, 2404-2409.
16. Singer, J.W.; Shaffer, S.; Baker, B.; Bernareggi, A.; Stromatt, S.; Nienstedt, D.; Besman, M. Paclitaxel poliglumex (XYOTAX; CT-2103): In intracellularly targeted taxane. Anticancer Drugs 2005, 16, 243-254.
17. Van, S.; Das, S.K.; Wang, X.; Feng, Z.; Jin, Y.; Hou, Z.; Chen, F.; Pham, A.; Jiang, N.; Howell, S.B.; Yu, L. Synthesis, Characterization, and Biological Evaluation of Poly(L-ãglutamylglutamine)-Paclitaxel Nano-Conjugate. Int. J. Nanomed. 2010, 5, 825-837.
18. Auzenne, E.; Donato, N.J.; Li, C.; Leroux, E.; Price, R.E.; Farquhar, D.; Klostergaard, J. Superior Therapeutic Profile of Poly-L-glutamic acid-Paclitaxel Copolymer Compared with Taxol in Xenogeneic Compartmental Models of Human Ovarian Carcinoma. Clin. Cancer Res. 2002, 8, 573-581.
19. Zou, Y.; Fu, H.; Ghosh, S.; Farquhar, D.; Klostergaard, J. Antitumor Activity of Hydrophilic Paclitaxel Copolymer Prodrug Using Locoregional Delivery in Human Orthotopic Non-Small Cell Lung Cancer Xenograft Models. Clin. Cancer Res. 2004, 10, 7382-7391.
20. Li, C.; Price, J.E.; Milas, L.; Hunter, N. R.; Ke, S.; Yu, D-F.; Charnsangavej, C.; Wallace, S. Antitumor Activity of Poly(L-glutamic acid)-Paclitaxel on Syngeneic and Xenografted Tumors. Clin. Cancer Res. 1999, 5, 891-897.
21. Wang, X.; Zhao, G.; Van, S.; Jiang, N.; Yu, L.; Vera, D.; Howell, S.B. Pharmacokinetics and tissue distribution of PGG-paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenografts. Cancer Chemother. Pharmacol. 2010, 65, 515-526.
22. Feng, Z.; Zhao, G.; Yu, L.; Gough, D.; Howell, S. Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane. Cancer Chemot her. Pharmacol. 2010, 65, 923-930.
23. Li, C.; Newman, R.A.; Wu, Q.P.; Ke, S.; Chen, W.; Hutto, T.; Kan, Z.; Brannan, M. D.; Charnsangavej, C.; Wallace, S. Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor. Cancer Chemother. Pharmacol. 2000, 46, 416-422.
24. Hamaguchi, T.; Matsumura, Y.; Suzuki, M.; Goda, R.; Nakamura, I.; Nakatomi, I.; Yokoyama, M.; Kataoka, K.; Kakizoe, T. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br. J. Cancer 2005, 92, 1240-1246.
25. Kim, S.C.; Kim, D.W.; Shim, Y.H.; Bang, J.S.; Oh, H.S.; Kim, S.W.; Seo, M.H. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J. Control. Release 2001, 72, 191-202.
26. Kim, T.-Y.; Kim, D.-W.; Chung, J.-Y.; Shin, S.G.; Kim, S.-C.; Heo, D.S.; Kim, N.K.; Bang, Y.-J. Phase I ad pharmacokinetic study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies. Clin. Cancer Res. 2004, 10, 3708-3716.
27. Hamaguchi, T.; Kato, K.; Yasui, H.; Morizane, C.; Ikeda, M.; Ueno, H.; Muro, K.; Yamada, Y.; Okusaka, T.; Shirao, K.; Shimada, H.; Nakahama, H.; Matsumura, Y. A Phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br. J. Cancer 2007, 97, 170-176.
28. Sabbatini, P.; Aghajanian, C.; Dizon, S.; Dupont, J.; Brown, J.V.; Peters, W.A.; Jacobs, A.; Mehdi, A.; Rivkin, S.; Eisenfeld, A.; Spriggs, D. Phase II study of CT-2103 in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma. J. Clin. Oncol. 2004, 22, 4523-4531.
29. Sabbatini, P.; Sill, M.W.; O'Malley, D.; Adler, L.; Secord, A.A. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): A gynecologic oncology group study. Gynecol. Oncol. 2008, 111, 455-460.
30. Beer, T.M.; Ryan, C.; Alumkal, J.; Ryan, C.W.; Sun, J.; Eilers, K.M. A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Anticancer Drugs 2010, 21, 433-438.
31. Percorelli, S.; Favalli, G.; Gadducci, A.; Katsaros, D.; Panici, P.B.; Carpi, A.; Scambia, G.; Ballardini, M.; Nanni, O.; Conte, P.F. Phase III trial of Observation versus Six Courses of Paclitaxel in Patients with Advanced Epithelial Ovarian Cancer in Complete Response After Six Courses of Paclitaxel/Platinum-based Chemotherapy: Final Results of the After-6 Protocol 1. J. Clin. Oncol. 2009, 27, 4642-4648.
32. Lim, W.T.; Tan, E.H.; Toh, C.K.; Hee, S.W.; Leong, S.S.; Ang, P.C.S.; Wong, N.C.; Chowbay, B. Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol®-PM) in patients with solid tumors. Ann. Oncol. 2010, 21, 382-388.
33. Wiernik, P.H.; Schwartz, E.L.; Strauman, J.J.; Dutcher, J.P.; Lipton, R.B.; Paietta, E. Phase I Clinical and Pharmacokinetic Study of Taxol. Cancer Res. 1987, 47, 2486-2493.
34. McGuire, W.P.; Hoskins, W.J.; Brady, M.F.; Kucera, P.R.; Partridge, E.E.; Look, K.Y.; Clarke-Pearson, D.L.; Davidson, M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 1996, 334, 1-6.
35. Tannock, I.F.; de Wit, R.; Berry, W.R.; Horti, J.; Pluzanska, A.; Chi, K.N.; Oudard, S.; Théodore, C.; James, N.D.; Turesson, I.; Rosenthal, M. A.; Eisenberger, M. A. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. N. Engl. J. Med. 2004, 351, 1502-1512.
36. Petrylak, D.P.; Tangen, C.M.; Hussain, M.H.A.; Lara, P.N.; Jones, J.A.; Taplin, M.D.; Burch, P.A.; Berry, D.; Moinpour, C.; Kohli, M.; Benson, M.C.; Small, E.J.; Raghavan, D.; Crawford, E.D. Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer. N. Engl. J. Med. 2004, 351, 1513-1520.
37. Jones, S.E.; Erban, J.; Overmoyer, B.; Budd, G. T.; Hutchins, L.; Lower, E.; Laufman, L.; Sundaram, S.; Urba, W.J.; Pritchard, K.I.; Mennel, R.; Richards, D.; Olsen, S.; Meyers, M.L.; Ravdin, P. M. Randomized Phase III Study of Decetaxel Compared with Paclitaxel in Metastatic Breast Cancer. J. Clin. Oncol. 2005, 23, 5542-5551.
38. Di Leo, A.; Gomez, H.L.; Aziz, Z.; Zvibule, Z.; Bines, J.; Arbushites, M.C.; Guerrera, S.F.; Koehler, M.; Oliva, C.; Stein, S.H.; Williams, L.S.; Dering J.; Finn, R.S.; Press, M.F. Phase II, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel with Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer. J. Clin. Oncol. 2008, 26, 5544-5552.
39. Paridaens, R.; Biganzoli, L.; Bruning, P.; Klijn, J.G.M.; Gamucci, T.; Houston, S.; Coleman, R.; Schachter, J.; Van Vreckem, A.; Sylvester, R.; Awada, A.; Wildiers, J.; Piccart, M. Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over. J. Clin. Oncol. 2000, 18, 724-733.
40. Lin, N.U.; Parker, L.M.; Come, S.E.; Burstein, H.J.; Haldoupis, M.; Ryabin, N.; Gelman, R.; Winer, E. P.; Shulman, L. N. Phase II study of CT-2103 as a first-or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest. New Drugs 2007, 25, 369-375.
41. Lee, K.S.; Chung, H.C.; Im, S.A.; Park, Y.H.; Kim, C.S.; Kim, S-B.; Rha, S.Y.; Lee, M.Y.; Ro, J. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res. Treat. 2008, 108, 241-250.
42. Socinski, M.A.; Ivanova, A.; Bakri, K.; Wall, J.; Baggstrom, M.Q.; Hensing, T.A.; Mears, A.; Tynan, M.; Beaumont, J.; Peterman, A.H.; Niell, H.B. A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Ann. Oncol. 2006, 17, 104-109.
43. Yoshimura, N.; Kudoh, S.; Mukohara, T.; Yamauchi, S.; Yamada, M.; Kawaguchi, T.; Hirata, K.; Yoshikawa, J. Phase I/II study of cisplatin combined with weekly paclitaxel in patients with advanced non-small-cell lung cancer. Br. J. Cancer 2004, 90, 1184-1189.
44. Rosell, R.; Gatzemeier, U.; Betticher, D.C.; Keppler, U.; Macha, H. N.; Pirker, R.; Berthet, P.; Breau, J.L.; Lianes, P.; Nicholson, M.; Ardizzoni, A.; Chemaissani, A.; Bogaerts, J.; Gallant, G. Phase III randomized trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann. Oncol. 2002, 13, 1539-1549.
45. Kelly, K.; Crowley, J.; Bunn, P.A. Jr.; Presant, C.A.; Grevstad, P.K.; Moinpour, C.M.; Ramsey, S.D.; Wozniak, A.J.; Weiss, G.R.; Moore, D.F.; Israel, V.K.; Livingston, R.B.; Gandara, D.R. Randomized Phase III trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients with Advanced Non-Small-Cell Lung Cancer: A Southwest Oncology Group Trial. J. Clin. Oncol. 2001, 19, 3210-3218.
46. O'Brien, M.E.R.; Socinski, M.A.; Popovich, A.Y.; Bondarenkok, I.N.; Tomova, A.; Bilynskyi, B. T.; Hotko, Y.S.; Ganul, V.L.; Kostinsky, I.Y.; Eisenfeld, A.J.; Sandalic, L.; Oldham, F.B.; Bandstra, B.; Sandler, A.B.; Singer, J.W. Randomized Phase III Trial Comparing Sing-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent gemcitabine or vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer. J. Thorac. Oncol. 2008, 3, 728-734.
47. Paz-Ares, L.; Ross, H.; O'Brien, M.; Riviere, A.; Gatzemeier, U.; Von Pawel, J.; Kaukel, E.; Freitage, L.; Digel, W.; Bischoff, H.; Garcia-Campelo, R.; Lannotti, N.; Reiterer, P.; Bover, I.; Prendiville, J.; Eisenfeld, A.J.; Oldham, F.B.; Bandstra, B.; Singer, J.W.; Bonomi, P. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br. J. Cancer 2008, 98, 1608-1613.
48. Langer, C.J.; O'Byrne, K.J.; Socinski, M.A.; Mikhailove, S.M.; Leśniewski-Kmak, K.; Smakal, M.; Ciuleanu, T.E.; Orlove, S.V.; Dediu, M.; Heigener, D.; Eisenddeld, A.J.; Snadalic, L.; Oldham, F.B.; Singer, J.W.; Ross, H.J. Phase III Trial comparing Paclitaxel Poliglumex (CT-2103, PPX) in combination with Carboplatin Versus Standard paclitaxel and Carboplatin in the Treatment of PS 2 patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer. J. Thorac. Oncol. 2008, 3, 623-630.
49. Kim, D.-W.; Kim, S.-Y.; Kim, H.-K.; Kim, S.-W.; Shin, S.W.; Kim, J.S.; Park, K.; Lee, M.Y.; Heo, D.S. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small cell lung cancer. Ann. Oncol. 2007, 18, 2009-2014.
50. Kim, N.; Jung, H.C. The role of Serum Pepsinogen in the Detection of Gastric Cancer. Gut. Liver 2010, 4, 307-319.
51. Gadgeel, S.M.; Shields, A.F.; Heilbrun, L.K.; Labadidi, S.; Zalupski, M.; Chaplen, R.; Philip, P.A. Phase II Study of Paclitaxel and Carboplatin in Patients with Advanced Gastric Cancer. Am. J. Clin. Oncol. (CCT) 2003, 26, 37-41.
52. Sun, Q.; Liu, C.; Zhong, H.; Zhong, B.; Xu, H.; Shen, W.; Wang, D. Multi-center Phase II Trial of Weekly Paclitaxel Plus Cisplatin Combination Chemotherapy in Patients with Advanced Gastric and Gastro-esophageal cancer. Jpn. J. Clin. Oncol. 2009, 39, 237-243.
53. Yamada, Y.; Shirao, K.; Ohtsu, A.; Boku, N.; Hyodo, I.; Saitoh, H.; Miyata, Y.; Taguchi, T. Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann. Oncol. 2001, 12, 1133-1137.
54. Chin, K.; Kato, K.; Yoshikawa, T.; Yamaguchi, K.; Esaki, T.; Tsuji, Y.; Sakai, K.; Kimura, M.; Ikeda, R.; Matsumura, Y. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle as second-line treatment for advanced or recurrent gastric cancer. J. Clin. Oncol. 2010, 28, 15s (suppl. Abstract 4041).